Key Takeaway: Nurix is committed to translating novel scientific insights into innovative therapies aimed at combating cancer and autoimmune diseases. The company is advancing its multi-modal portfolio, which includes both wholly owned and partnered assets. This approach highlights their focus on targeted protein degraders as potential next-generation antibody payloads.
Price reaction · baseline $23.33 (2024-09-06 close) · hit pre-market · 1 other NRIX headline(s) in the window, move may be shared
day 0 close
+0.5%
Market Sentiment Analysis
POSITIVE FACTORS
Focus on novel scientific insights.
Advancement of multi-modal portfolio.
Commitment to breakthrough therapies.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+85%
120-day peak, hindsight
Typical move
4.4%
average across 9 past catalysts
Cash runway
~14 mo
Low dilution risk
Lead asset
NX-5948
Phase 3 · B-cell Lymphoma
Full Press Release Details
RESOURCE LIBRARY
RESOURCE LIBRARY
At Nurix, we are dedicated to translating novel scientific insights into breakthrough therapies, advancing our multi-modal portfolio of wholly owned and partnered assets to outmatch cancer and autoimmune disease. Access our protein degradation resources below.
Filter by
Frequently Asked Questions
What is Nurix focused on?
Nurix is dedicated to translating novel scientific insights into breakthrough therapies.
What diseases does Nurix target?
Nurix aims to combat cancer and autoimmune diseases.
What type of portfolio does Nurix have?
Nurix has a multi-modal portfolio of wholly owned and partnered assets.
What are targeted protein degraders?
Targeted protein degraders are innovative therapies being explored by Nurix.